Zepbound Clinical Trial Findings - Search News

News

Zepbound beats Wegovy for weight loss

Associated Press News on MSN · 3d

Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical trial participants who took tirzepatide,

Becker's Hospital Review · 2d

Zepbound beats Wegovy for weight loss: Study

Eli Lilly’s weight loss drug Zepbound led to significantly greater weight loss than Novo Nordisk’s Wegovy in a 72-week, head-to-head clinical trial, according to findings published in The New England Journal of Medicine and presented at the European Congress on Obesity.

EconoTimes · 2d

Eli Lilly’s Zepbound Outperforms Wegovy in Weight Loss Head-to-Head Trial

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key weight-loss metrics, including waist circumference reduction. Results from the

2d

Why patients are being forced to switch to a 2nd-choice obesity drug

CVS Caremark decided to stop offering one product in favor of another for weight loss, the latest example of ...

Dual-target weight-loss drug is 47% more effective than its rival

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results